Skip to main content
Premium Trial:

Request an Annual Quote

MDRNA Amends Deal for UNA Tech to Eliminate Payments to Licensor, Regains Nasdaq Compliance

Premium

This article has been updated from a version posted June 22 to include an update on the company's Nasdaq listing status.

MDRNA announced last week that it has acquired from RiboTask the full financial and transactional rights to its unlocked nucleobase analog technology for the development of RNA therapeutics.

Separately this week, the company announced that it has regained full compliance with the listing requirements of the Nasdaq Global Market, specifically the $1 minimum per share losing bid price and $50 million minimum market value for listed securities.

MDRNA said that its deal for the UNA technology, which was announced late last year (see RNAi News, 10/23/2008), included "certain financial obligations" to RiboTask in the event of a license, development, or sale of the UNA-based siRNAs as human therapeutics.

Under the new terms of the arrangement, all future financial obligations to RiboTask have been eliminated, MDRNA said. RiboTask retains the rights to make, sell, and sublicense the UNA technology for research and diagnostic purposes.

Additional terms of the amended deal were not disclosed.

The UNA technology is comprised of an acyclic ribonucleoside analog in which the bond between C2' and C3' atoms is broken. The resultant change in sugar structure is designed to make the analog flexible and reduce the binding affinity of an siRNA's strands.

According to MDRNA, UNA-based siRNAs are protected from enzymatic destruction, reduction, or elimination, and avoid cytokine responses, but remain highly effective.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.